Cadrenal appoints James J. Ferguson as CMO; Dr. Douglas Losordo departs

Cadrenal Therapeutics, Inc.

Dr. Ferguson, over 25 years cardiovascular experience, appointed Chief Medical Officer effective Feb 5, 2025.
Annual base salary of $505,000; discretionary bonus up to 40% of base; option grant of 60,000 shares.
Dr. Losordo separated amicably; severance includes 6-month salary continuation, bonus, and accelerated vesting.
Dr. Ferguson to lead late-stage clinical development of tecarfarin including pivotal LVAD trial.
Compensation includes option vesting: 25% on Mar 1, 2026, balance pro rata over 36 months.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

James J. Ferguson III

Chief Medical Officer

CVKD · Cadrenal Therapeutics, Inc.

Effective: 2025-02-05
Filed: February 7, 2025, 6:59 PM ET

On February 4, 2025, Cadrenal Therapeutics, Inc. (the “Company”) entered into an employment agreement with James J. Ferguson III (the “Employment Agreement”), effective as of February 5, 2025 (the “Effective Date”), to employ Dr. Ferguson as the Company’s Chief Medical Officer.

Departed

Douglas Losordo

Chief Medical Officer

CVKD · Cadrenal Therapeutics, Inc.

Effective: 2025-02-04
Successor: James J. Ferguson III
Filed: February 7, 2025, 6:59 PM ET

On February 4, 2025, the Company terminated its employment relationship with its Chief Medical Officer, Douglas Losordo, on a mutual amicable basis.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

James J. Ferguson III was appointed as Chief Medical Officer at Cadrenal Therapeutics, Inc..

Action: appointed
Role: Chief Medical Officer

Exact text from the filing

On February 4, 2025, Cadrenal Therapeutics, Inc. (the “Company”) entered into an employment agreement with James J. Ferguson III (the “Employment Agreement”), effective as of February 5, 2025 (the “Effective Date”), to employ Dr. Ferguson as the Company’s Chief Medical Officer.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Douglas Losordo was terminated as Chief Medical Officer at Cadrenal Therapeutics, Inc..

Action: terminated
Role: Chief Medical Officer

Exact text from the filing

On February 4, 2025, the Company terminated its employment relationship with its Chief Medical Officer, Douglas Losordo, on a mutual amicable basis.

View on SEC.gov

Cadrenal Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-25-011315

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.